Skip to contentE
Enveric Biosciences, Inc.
E
ENVBEnveric Biosciences, Inc. Q2 2020 · 10-Q
Revenue$8.25M$8.25M−25.1% vs Q2 2019 Net Income-$1.57M-$1.57MN/M vs Q2 2019 EPS Diluted-$0.48-$0.48N/M vs Q2 2019 Gross Profit$1,818,130−23.7% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Enveric Biosciences, Inc. · CIK 890821 · Engraved from SEC EDGAR
Operating Cash Flowderived-$571,321N/M Margins · derivedGross margin22.0%+0.4 pt vs Q2 2019
Operating margin-14.4%−1.0 pt vs Q2 2019
Net margin-19.1%−7.7 pt vs Q2 2019
ended Jun 30, 2020 · filed Aug 14, 2020 · 45 d after period end